Vijaya Diagnostic Centre has announced the approval of its amalgamation with Medinova Diagnostic Services Limited, effective November 4, 2025. The board also approved the Q2 2026 financial results, reporting a total income of ₹194.51 million and a profit after tax of ₹42.70 million. The amalgamation is expected to enhance operational efficiencies and market presence.
Amalgamation with Medinova Approved
The Board of Directors has officially approved the scheme of amalgamation between Vijaya Diagnostic Centre and Medinova Diagnostic Services Limited. The effective date of the scheme is November 4, 2025, marking a significant step in the company’s strategic growth. For every 22 shares of Medinova, shareholders will receive 1 share of Vijaya Diagnostic.
Key Details of the Amalgamation
As part of the amalgamation, Medinova Millennium MRI Services LLP will become a wholly-owned subsidiary of Vijaya Diagnostic Centre. Additionally, the authorized share capital of the company will increase to ₹230.5 million.
Q2 2026 Financial Performance
Vijaya Diagnostic Centre reported its unaudited financial results for Q2 2026. Key financial highlights include:
- Total Income: ₹194.51 million
- Profit Before Tax: ₹57.05 million
- Profit After Tax: ₹42.70 million
Year-to-Date Performance
The company’s year-to-date performance showed positive trends:
- Total Income: ₹378.46 million
- Profit Before Tax: ₹110.18 million
- Profit After Tax: ₹81.45 million
Balance Sheet Highlights
Key figures from the unaudited balance sheet include:
- Total Equity: ₹865.07 million
- Total Assets: ₹1390.70 million
Cash Flow Statement
Significant points from the cash flow statement:
- Net cash inflow from operating activities: ₹138.65 million
- Net cash used in investing activities: ₹84.02 million
Source: BSE